Home › Research › Biomarkers
Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline
Jetske van der Schaar, Wiesje M. van der Flier, Leonie N.C. Visser, Elsmarieke van de Giessen, Argonde C. van Harten, Sietske A.M. Sikkes, Mardou S. S. A. van Leeuwenstijn‐Koopman, Heleen M. A. Hendriksen et al.. Alzheimer s Research & Therapy, 2026-03-27
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Participants’ motivations for testing and long-term adaptation to the results were strongly shaped by cognitive concerns and personal experiences of dementia in relatives. All demonstrated accurate comprehension of their amyloid status. Those with negative scans described immediate relief and reattributed memory lapses to normal aging, while recognizing that the reassurance was provisional. Although positive scans provoked initial shock and fear of deterioration, participants valued information over uncertainty, and over time, fear attenuated as they perceived no rapid decline. Both groups regarded results as meaningful and personally actionable, informing health behavior, life priorities, and preparations for future decline. Fourteen of 17 participants spontaneously mentioned considering options for self-determined end-of-life. Regardless of amyloid status, most participants shared their result with close relatives and friends, some also informed colleagues or acquaintances, while others limited communication to avoid stigma, protect loved ones, or reduce the burden of repeated explanations. Participants valued testing, expressed no regret, and would choose disclosure again. Three years after disclosure, participants generally had adjusted to living with their imaging result, finding personal meaning and practical engagement without reporting ongoing psychological harm. Some reported residual concerns and uncertainty, irrespective of amyloid status. These findings offer timely guidance for clinicians and patients as biomarker disclosure is more widely incorporated into routine practice.
What this study adds
Evidence grade: Moderate
The record lists 17 participants. Three years after learning their amyloid PET results, people with subjective cognitive decline had adjusted to living with the information without ongoing psychological harm and valued testing. This addresses the experience of disclosure rather than treating, curing or preventing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
van der Schaar, J., van der Flier, W. M., Visser, L. N., van de Giessen, E., van Harten, A. C., Sikkes, S. A., et al. (2026). Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline. Alzheimer s Research & Therapy. https://doi.org/10.1186/s13195-026-02026-3
Vancouver
van der Schaar J, van der Flier WM, Visser LN, van de Giessen E, van Harten AC, Sikkes SA, et al. Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline. Alzheimer s Research & Therapy. 2026. doi:10.1186/s13195-026-02026-3. PMID: 41896998.
BibTeX
@article{vanderschaar2026-41896998,
author = {van der Schaar, Jetske and van der Flier, Wiesje M. and Visser, Leonie N.C. and van de Giessen, Elsmarieke and van Harten, Argonde C. and Sikkes, Sietske A.M. and van Leeuwenstijn‐Koopman, Mardou S. S. A. and Hendriksen, Heleen M. A. and others},
title = {{Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline}},
journal = {Alzheimer s Research \& Therapy},
year = {2026},
doi = {10.1186/s13195-026-02026-3},
pmid = {41896998},
url = {https://doi.org/10.1186/s13195-026-02026-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Participants’ motivations for testing and long-term adaptation to the results were strongly shaped by cognitive concerns and personal experiences of dementia in relatives.
- All demonstrated accurate comprehension of their amyloid status.
- Those with negative scans described immediate relief and reattributed memory lapses to normal aging, while recognizing that the reassurance was provisional.
- Although positive scans provoked initial shock and fear of deterioration, participants valued information over uncertainty, and over time, fear attenuated as they perceived no rapid decline.
- Both groups regarded results as meaningful and personally actionable, informing health behavior, life priorities, and preparations for future decline.
Why it matters
Three years after learning their amyloid PET results, people with subjective cognitive decline had adjusted to living with the information without ongoing psychological harm and valued testing. This addresses the experience of disclosure rather than treating, curing or preventing the disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants17
- Evidence strengthModerate
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s Research & Therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 1 / 4 | 17 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Eva C. A. Asscher: h-index 0 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Utrecht University: institution h-index 1,157 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41896998) |
| Free to read | 2 / 2 | Free to read |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-026-02026-3
- PubMed: 41896998
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.